A bicentre open label randomised pilot study for proof of safety and efficacy of immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1-FV versus a depot extract of natural birch allergen.

Trial Profile

A bicentre open label randomised pilot study for proof of safety and efficacy of immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1-FV versus a depot extract of natural birch allergen.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2013

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top